Michael Catelani

Michael Catelani, listed as finance chief, appears in our data through filings on Anixa Biosciences Inc shares, published by SEC (Form 4). Between 18 September 2018 and 30 September 2026, the trades on record add up to 18 filings.

Purchases make up the whole of the open-market record (7 purchases, €93k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants. In 2026 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €14k. Clusters matter here: 4 out of 7 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 30 September 2026: an open-market purchase of €14k, in Anixa Biosciences Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.